Nanobiotix S.A.
NANO.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | -€11,609 | €30,058 | €4,776 | €10 |
| % Growth | -138.6% | 529.4% | 47,660% | – |
| Cost of Goods Sold | €0 | €0 | €1,500 | -€2,637 |
| Gross Profit | -€11,609 | €30,058 | €3,276 | €2,647 |
| % Margin | 100% | 100% | 68.6% | 26,470% |
| R&D Expenses | €40,541 | €38,396 | €31,471 | €29,234 |
| G&A Expenses | €20,059 | €21,661 | €0 | €19,017 |
| SG&A Expenses | €20,059 | €21,661 | €17,479 | €19,018 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €1 |
| Other Operating Expenses | -€3,817 | -€3,220 | €43 | €6,974 |
| Operating Expenses | €56,783 | €56,837 | €48,993 | €55,226 |
| Operating Income | -€68,392 | -€26,779 | -€50,493 | -€52,579 |
| % Margin | 589.1% | -89.1% | -1,057.2% | -525,790% |
| Other Income/Exp. Net | €361 | -€12,801 | -€10,629 | €5,581 |
| Pre-Tax Income | -€68,031 | -€39,580 | -€61,122 | -€49,489 |
| Tax Expense | €101 | €120 | -€4,081 | -€2,486 |
| Net Income | -€68,132 | -€39,700 | -€57,041 | -€47,003 |
| % Margin | 586.9% | -132.1% | -1,194.3% | -470,030% |
| EPS | -1.44 | -1.08 | -1.64 | -1.35 |
| % Growth | -33.3% | 34.1% | -21.5% | – |
| EPS Diluted | -1.44 | -1.08 | -1.64 | -1.35 |
| Weighted Avg Shares Out | 47,265 | 36,759 | 34,852 | 34,733 |
| Weighted Avg Shares Out Dil | 47,265 | 36,928 | 34,852 | 34,733 |
| Supplemental Information | – | – | – | – |
| Interest Income | €2,629 | €1,217 | €256 | €671 |
| Interest Expense | €8,085 | €7,982 | €5,837 | €671 |
| Depreciation & Amortization | €1,622 | €1,513 | €1,500 | €1,560 |
| EBITDA | -€61,624 | -€30,085 | -€53,785 | -€45,605 |
| % Margin | 530.8% | -100.1% | -1,126.2% | -456,050% |